Home Blog Page 2

COOPER PHARMA and OSI sign distribution agreement to protect and prevent against respiratory viruses, including the one that causes COVID-19


BROSSARD, QC and Casablanca, Morocco, August 11, 2021 / CNW / – An innovative broad-spectrum natural organic barrier is needed to prevent viral respiratory infections. COOPER PHARMA and OSI have signed a distribution agreement to market Flavobac ™ Cold & Flu Guard ™. Under the terms of this agreement, OSI grants COOPER PHARMA the exclusive right to distribute Flavobac ™ Cold & Flu Guard ™ in Morocco and the United Arab Emirates (UNITED ARAB EMIRATES). COOPER PHARMA and its affiliates will use their sales, marketing and e-commerce expertise to distribute Flavobac ™ Cold & Flu Guard ™ once product registration has been obtained from Moroccan and UAE health authorities.

Flavobac ™ Cold & Flu Guard ™ will become an essential part of COOPER PHARMA’s medical solutions, to protect children, parents, healthcare professionals and society against respiratory viruses including SARS-CoV-2 which causes COVID- 19. “COOPER PHARMA is committed to helping reduce the impact of respiratory viral infections” declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA.

Christian Sauvageau, President of OSI, said: “We are extremely proud of this opportunity to work with such a forward-thinking company as COOPER PHARMA. We have seen COOPER PHARMA’s total determination to bring innovative solutions to market and we are delighted to work with them. We also thank The Harel Group for identifying COOPER PHARMA as a strategic partner and for facilitating the entire transaction process, from the introduction to the execution of final agreements with COOPER PHARMA. “

Flavobac ™ Cold & Flu Guard ™ is a formulation based on a substance obtained from a natural source. It fights viruses by interfering with their ability to adhere to the oral and nasal mucosa. Flavobac ™ Cold & Flu Guard ™ has been shown to kill “99.8% of SARS-CoV-2 within 5 minutes as well as many other respiratory viruses such as human coronavirus, influenza virus, rhinovirus and VRS1. Flavobac ™ Cold & Flu Guard ™ is already registered in Europe, Canada and the United States. Efforts are underway to enable its use around the world. For more information, see www.coldandfluguard.com

“COOPER PHARMA is proud to receive the distribution rights of Flavobac ™ Cold & Flu Guard ™ from our partner OSI in order to help people and healthcare professionals to protect themselves against respiratory viral infections, while respecting of course and above all the health recommendations in terms of prevention and treatment against respiratory viruses and in particular SARS-CoV-2 “declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA. “An innovative broad-spectrum barrier to help reduce viral spread and viral loads is an important new option for protecting against respiratory viruses. Flavobac ™ Cold & Flu Guard ™ can neutralize viruses that have entered the nose and mouth and act as “local disinfectants” to destroy viruses before they have a chance to cause infection. Morocco, COOPER PHARMA is happy to provide people with a new tool to protect themselves against respiratory viruses, ”said Ayman Cheikh-Lahlou.

Since 1933, Cooper Pharma, a Moroccan pharmaceutical company, has supported health professionals in the service of a mission: to increase access to medicines for all. Cooper Pharma is today a leading laboratory in the national pharmaceutical industry, with its range of Cooper products, covering more than a hundred specialties and major therapeutic areas. Alongside its own products, Cooper Pharma is the partner of around twenty multinationals for which it represents around a hundred drugs, under license. Cooper Pharma is a producer, distributor and exporter of pharmaceutical specialties. Cooper Pharma is today a benchmark player in the Africa and Middle East region with commercial reach in Europe. Cooper Pharma has nine pharmaceutical factories that are wholly owned or in JV with local leaders on North Africa, West Africa, East Africa, the Gulf Cooperation Council countries and Europe. For more information, please visit: https://cooperpharma.ma/en/

About OSI
Oral Science International (OSI) is an innovation-driven company dedicated to the development and commercialization of innovative biotechnologies, providing solutions to oral / nasal infections and inflammation. Oral Science International has a strong and passionate management team committed to innovative oral care and infection control technologies that improve the quality of life for people of all ages. We are committed to customer-centric design and science-driven innovation. We are focused on providing safe, valuable and easy to use products for the global market. Our commitment to innovation, partnership and excellence rests on the foundation of a culture that greatly values ​​collaboration. We are guided by in-depth research that we share through publications and presentations, and in collaboration with all stakeholders. www.oralscience.com

About the Harel group
The Harel Group is a business development consultancy with in-depth industry knowledge and an extensive network of contacts in the pharmaceutical, biotechnology, diagnostics and medical devices sectors. The Harel Group supports clients looking to expand their global business footprint by identifying strategic partners and facilitating licensing and distribution agreements. For more information, please visit: https://www.theharelgroup.com/

  • Efficacy of the bioflavonoid spray against respiratory viruses, Z Cheikh, H Lerner, Oral health, July 9, 2021
  • SOURCE Oral Science International

    Source link

    Vallon Pharmaceuticals will present at Q3 Virtual


    Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18e 12:30 PM HEY

    PHILADELPHIA, PA, Aug 11, 2021 (GLOBE NEWSWIRE) – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs designed to deter abuse in the treatment of the central nervous system (CNS ), today announced that David Baker, President and CEO of Vallon, will be presenting at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 p.m. ET.

    In addition to the presentation, management will be available to participate in one-on-one virtual meetings with qualified members of the investment community who have registered to attend the conference. For more information on the conference, please visit the conference website.

    A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.

    About Vallon Medications, Inc.

    Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania. The Company is focused on the development of new drugs to help patients with central nervous system (CNS) disorders. The Company’s lead product candidate, ADAIR, is a novel immediate-release amphetamine abuse deterrent formulation under development for the treatment of ADHD and narcolepsy.

    For more information about the company, please visit www.vallon-pharma.com or contact us on LinkedIn or Twitter.

    References and links to websites have been provided as a convenience, and the information contained on such website does not form part of, or by reference to, this press release. Vallon is not responsible for the content of third party websites.

    Investor Contact:
    JTC Team, LLC
    Jenene thomas
    (833) 475-8247

    Source link

    Health Supplements Market – Short and Long Term Impact of Covid-19 on the Market-2021-2027


    Latest Data Lab Forecast Post “2021-2028 Health Supplements Market Research Report” provides an overview of the drivers and constraints that exist in the market. It evaluates historical data on the health supplements market and compares it with current market trends to enable readers to have a detailed analysis of the development of the market. A team of subject matter experts provided readers qualitative and quantitative data on the market and the various elements associated with it.

    The research report is divided into chapters, which are introduced by the executive summary. This is the introductory part of the chapter which provides details of the global market figures, both historical and estimated. The summary also gives a brief overview of the segments and the reasons for the rise or fall during the forecast period. The Insightful Research Report on the Health Supplement Market Involves Porter’s Five Forces Analysis and SWOT Analysis to help understand the factors that affect consumer and seller behavior.

    Get | Download a sample copy with table of contents, graphics and list of figures @

    North America is expected to hold a dominant position in the global health supplements market, owing to the increase in collaborative activities of major players during the forecast period.

    The report provides a detailed analysis of the major market players along with an overview of their business, expansion plans, and strategies. The main players examined in the report are:

    ?? Amway, Cosway, Herbalceutical, Herbalife, Astana Biocare, Bioalpha, Dynapham Herbal, Era Herbal, QD Herbs, White Heron Pharmaceuticals

    The scope of the report:

    The report segments the health supplements market on the basis of application, type, service, technology, and region. Each chapter of this segmentation allows readers to grasp the intricacies of the market. An expanded view of segment analysis aims to bring readers closer to market opportunities and risks. It also examines the policy scenarios that are expected to affect the market on a large and small scale.

    The Health Supplements Market report studies the changing regulatory scenarios to create accurate predictions on potential investments. It also assesses the risk to new entrants and the intensity of competitive rivalry.

    The report further studies the market segmentation on the basis of the types of products offered in the market and their end uses.

    By Product Type, the market is primarily split into:
    ⇛ Vitamins and dietary supplements, weight management products, herbal and traditional products.

    By application, this report covers the following segments:
    Infants, children, adults, pregnant women, the elderly.

    We are currently offering an end of quarter discount to all of our high potential clients and we would really like you to take advantage of the benefits and use your analysis based on our report.

    Get a discount on purchasing this report @https://www.datalabforecast.com/request-discount/238287-health-supplement-market

    Health Supplements Market
    Health Supplements Market

    Scope of Health Supplements Market Report

    Due to regional segmentation, the market is divided into major regions North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. Further, the regional analysis covers the market split and major players by country.

    The research report offered by Data Lab Forecast provides an updated view of the global health supplements market. The report provides a detailed analysis of key trends and emerging market factors that might affect the growth of the industry. Additionally, the report studies the market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market.

    The key responses captured in the study are

    • Which geography would have better demand for products / services?
    • What strategies of the major players allow them to acquire a share of the regional market?
    • Which countries can see the sharp increase in CAGR and year-over-year growth?
    • How feasible is the long-term investment market?
    • What opportunity would the country offer to existing and new players in the health supplements market?
    • Analysis of the risks involved with suppliers in a specific geographic area?
    • What are the factors influencing the demand for health supplements in the near future?
    • What is the impact analysis of various factors in the growth of the Health Supplement market?
    • What are the recent trends in the regional market and how successful are they?

    Buy now this premium report to develop your [email protected] https://www.datalabforecast.com/buy-now/?id=238287-health-supplement-market&license_type=su

    This Health Supplements report covers key elements such as market trends, market share, size, and aspects driving the growth of the companies operating in the market to assist readers in implementing profitable strategies for accelerate the growth of their business. This report also analyzes the expansion, market size, key segments, market share, applications, major drivers, and restraints.

    About Us

    Turn information into information

    We pride ourselves on being a niche market intelligence, strategic consulting and reporting company aimed at making a powerful impact on businesses around the world. Our precision estimation and forecasting models have been recognized in the majority of business forums.

    We get online reports from some of the best publishers and continue to update our collection to bring you direct online access to the world’s most comprehensive and up-to-date database with qualified perceptions on industries, global products, establishments and trends. At ‘Data Lab Forecast’, we aim to help our clients strategize and formulate business policies and achieve tremendous growth in their respective market area. Data Lab Forecast is a one-stop-shop solution provider ranging from data collection and data outsourcing, investment advice, business modeling and strategic planning. The company strengthens clients’ knowledge on factors such as strategies, future estimates, growth or fall forecasts, opportunity analysis and consumer surveys, among others.


    Henri k
    Data Lab Forecasts
    86, avenue Van Wagenen, Jersey,
    New Jersey 07306, United States
    Telephone: +1 917-725-5253
    E-mail: [email protected]
    Website: https://www.datalabforecast.com/
    Follow us on: LinkedIN | Twitter |

    More Trend Reports by Data Lab Forecast:

    • 2021-2027 Global and Regional Pet Products Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report (Upgraded Version)
    • 2021-2027 Global and Regional Industrial Hand Protective Gloves Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report (Upgraded Version)
    • 2021-2027 Global and Regional Coaches Cup Industry Production, Sale and Consumption Status and Prospects Professional Market Research Report (Upgraded Version)

    Source link

    Sisolak chooses former senator Yvanna Cancela as chief of staff


    CARSON CITY, Nevada (AP) – Nevada Gov. Steve Sisolak has chosen Yvanna Cancela, a former state lawmaker who resigned in January to take a post in President Joe Biden’s administration, to become his next Chief of Staff.

    “She brings a unique understanding of state government, political experience and the ability to build broad coalitions,” the governor said in a statement Monday.

    Cancela, 33, will start as the most senior member of Sisolak’s senior staff on September 1 and replace current Chief of Staff Michelle White, who announced her intention to leave last month.

    She has worked in Nevada politics since 2010 when she moved to Las Vegas for the re-election campaign of former US Senator Harry Reid. She then served as political director of the powerful Culinary Workers Union and was appointed to a vacant seat in the State Senate in 2016, after Ruben Kihuen was elected to serve in the United States Congress.

    As the first Latina in the Nevada Senate, she gained a reputation as a progressive among Democrats for pushing efforts to expand oversight of the pharmaceutical industry through drug price transparency measures and to prevent evictions. . She was an early supporter of Biden’s 2020 campaign and spoke at the Democratic National Convention in August.

    Source link

    Algernon Pharmaceuticals (AGNPF) signs exclusive licensing agreement with Dartmouth College


    What’s going on with Algernon Pharmaceuticals?

    Algernon Pharmaceuticals (AGNPF) today announced that it has signed an exclusive licensing agreement with Dartmouth College to acquire the rights to a method of use patent for the treatment of neuroendocrine cancers. The company’s shares were trading up 4.22% at $ 0.07 on Monday.

    What does this mean for Algernon Pharmaceuticals?

    The agreement with Dartmouth includes license initiation, maintenance and milestone fees, as well as an ongoing royalty on sales.

    Speaking on Algernon’s Pancreatic Cancer Research Program and the use of Ifenprodil, Dr William North of Dartmouth College, concluded that Ifenprodil significantly and rapidly reduced the average size of solid tumors in about 50% in three days,

    “We are very satisfied with the outcome of our discussions with Dartmouth regarding the research work initiated by Professor North”, noted Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “Dartmouth is a world-class education center and its close affiliation with Dartmouth-Hitchcock Medical Health Center will be an asset as we advance our Ifenprodil-based cancer control program in clinical trials. “

    AGNPF has a Short Term Technical Rank of 9. Find out what this means to you and get the rest of the rank on AGNPF!

    Algernon Pharmaceuticals is a clinical-stage drug development company focused on the pathological areas of stroke, idiopathic pulmonary fibrosis (IPF) and chronic cough, and COVID-19. The company’s business model is very capital efficient and strives to deliver maximum shareholder value. Algernon’s unique approach to drug discovery is based on the concept of drug reorientation.

    Source link

    Vitamin and Mineral Supplements Market: Regional Industry Segmentation, Analysis by Production, Consumption, Revenue, and Growth Rate by 2026


    Global Vitamin and Mineral Supplements Market Report 2016-2026 is the latest research study to assess the market, highlight opportunities, analyze risks, and support strategic and tactical decision-making. Growth and regulatory influencing factors regarding the use of information, availability of highly reliable products in the market, and increasing operational efficiency of vitamin and mineral supplement players . The study provides information on market trends and development, drivers, capacities, technologies, and changing dynamics of the global Vitamin and Mineral Supplements market.

    A detailed SWOT analysis of Vitamin and Mineral Supplements market provides strategic insights into the strengths and weaknesses of key market players, categories and countries growth prospects, challenges and intimidations of current competition and market growth. future growth prospects, as well as global and regional market positions.

    The main types mentioned in the report are multivitamins, simple vitamins, multiminerals, simple minerals and the applications covered in the report are men, women, children, others etc.

    Get a sample PDF copy at https://www.insidemarketreports.com/sample-request/4/854956/Vitamin-&-Mineral-Supplement

    The main market players:

    General nutrition centers
    The pride of the puritan
    Webber Naturals
    Pfizer Inc.
    Daiichi sankyo
    Hainan Yangshengtang
    CSPC Pharmaceutical Group
    Sanofi China

    The Vitamin and Mineral Supplements Market report includes:

    • Market Outlook: Drivers and dynamics.
    • Market segmentation : By type, by application, by region.
    • Competitive landscape: Depends on manufacturers, suppliers and development trends.
    • Product revenue analysis: Market share, size, CAGR, current market analysis, market forecast 2021-2026.

    The reports cover major market developments in Vitamin and Mineral Supplements growth strategies. Various companies focus on organic growth strategies such as product launches, product approvals and others such as patents and events. The inorganic growth strategy activities observed in the market were acquisitions, partnerships and collaborations. These activities have paved the way for an expansion of the activities and customers of market players. The payers of the vitamin and mineral supplement market are destined for lucrative growth opportunities in the future with the increasing demand for vitamin and mineral supplements in the global market.

    Reasons for Buying Vitamin and Mineral Supplements Market Report

    • The Vitamin and Mineral Supplements market report provides driving factors affecting the growth of the market.
    • Vitamin and Mineral Supplements Market report provides qualitative and quantitative analysis of the market based on segmentation
    • The Vitamin and Mineral Supplement market report presents the market advancements and advancements during the forecast period.
    • This report helps in understanding where the market opportunities will be.
    • The report compares and assesses various options affecting the vitamin and mineral supplements market.
    • Competitive landscape of major market players, as well as new service / product launches, partnerships, technologies, business expansions and acquisitions, etc.
    • Vitamin and Mineral Supplements Market Consider the restrictions and restrictions that may hamper the market.

    An overview of the impact of COVID-19 on this market:

    Effect of COVID-19: The Vitamin and Mineral Supplements Market report studies the effect of Coronavirus (COVID-19) on the Vitamin and Mineral Supplement industry. Since December 2019, the COVID-19 infection has spread to nearly 180+ countries around the world, with the World Health Organization declaring it a general well-being crisis. The global effects of the Covid 2020 infection (COVID-19) are now starting to be felt, and will primarily influence the vitamin and mineral supplements market in 2020 and 2021.

    However, that too will pass. Growing support from governments and a few organizations can help in the fight against this exceptionally infectious disease. There are a few businesses that are struggling and some are thriving. Generally speaking, just about all areas are expected to be affected by the pandemic.

    We are making constant efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and skills, we will provide you with an effective corporate Covid outbreak review to help you put in place what lies ahead.

    Prudent assessment of the components shaping the size, share and direction of development of the Vitamin and Mineral Supplements market;

    • Point by point review of all market portions
    • An intensive evaluation of the provincial and serious elements of the market
    • In-depth assessment of the effect of the COVID-19 pandemic.

    Get the impact of Covid-19 in the vitamin and mineral supplement market at https://www.insidemarketreports.com/covid-19/4/854956/Vitamin-&-Mineral-Supplement

    Main points of the table of contents

    1 Vitamin and Mineral Supplements Market Overview

    2 Global Vitamin and Mineral Supplements Market Competition by Major Players

    3 Global Vitamin and Mineral Supplements Capacity, Production, Revenue (Value) by Region)

    4 Global Vitamin and Mineral Supplements Supply (Production), Consumption, Export, Import by Region

    5 Global Vitamin and Mineral Supplements Production, Revenue (Value), Price Trend by Type

    6 Global Vitamin and Mineral Supplements Market Analysis by Types

    Unique vitamin
    Multi Mineral
    Unique mineral

    7 Global Vitamin and Mineral Supplements Market Analysis by Applications


    8 Global Vitamin and Mineral Supplement Manufacturers Profiles / Analysis

    9 Analysis of Manufacturing Costs of Vitamin and Mineral Supplements

    10 Industrial chain, sourcing strategy and downstream buyers

    11 Analysis of the marketing strategy, distributors / traders

    12 Analysis of market effect factors

    13 Global Vitamin and Mineral Supplements Market Forecast

    14 Research findings and conclusion

    15 Appendix

    Buy this report now with up to 40% discount and free consultation.
    Limited offer only.

    Why the domestic market reports:

    • Explore the extensive library of market reports
    • Precise and actionable information
    • Focus on key trends and market movements
    • Execution of critical consulting project
    • 24/7 online and offline support
    • Most detailed market segmentation

    For all your research needs, contact us at:

    E-mail: [email protected]

    Phone: + 1-617-230-0741

    Read more reports

    Carbon Tetrachloride (CTC) Market 2021-2026: Global Size, Share, Key Players, Production, Growth, and Future Prospects

    Specialty Greases Market Business Status, Industry Outlook 2020, and Key 13 Players (Wilmar, AAK AB, Cargill, IOI Group, more)

    Portable Piston Compressors Market: Global Industry Analysis 2020-2026 by Types, Applications and Key Players

    Source link

    Chemicals and Pharmaceuticals Exports Increase 13.94%


    Exports of chemicals and pharmaceuticals in fiscal year 2020-21 increased by 13.94% compared to exports in the corresponding period last year

    ISLAMABAD (UrduPoint / Pakistan Point News – August 9, 2021): Exports of chemicals and pharmaceuticals in fiscal year 2020-21 increased by 13.94% compared to exports in the corresponding period last year.

    During the period July 20 to June 21, chemicals and pharmaceuticals worth US $ 1,148,943,000 were exported compared to US $ 1,008,407,000 in the same period last year.

    According to data released by the Pakistan Bureau of Statistics, exports of plastics increased 9.03 percent, valued at US $ 322,709 thousand compared to exports of US $ 295,970 thousand from the same period of last year.

    Meanwhile, pharmaceutical exports increased by 28.46 percent, valued at US $ 270,142,000 were also exported in the current fiscal year compared to exports valued at 210 US $ 299,000 from the same period last year.

    During the period under review, exports of other chemicals increased by 10.74 percent, valued at US $ 556,092,000 were exported in the current fiscal year compared to exports from valued at US $ 502,138,000 from the same period last year.


    Source link

    Global Isopropyl Alcohol (IPA) Market Outlook to 2026 – ResearchAndMarkets.com


    DUBLIN – (COMMERCIAL THREAD) – “Global Isopropyl Alcohol (API) Market Outlook to 2026” report has been added to ResearchAndMarkets.com offer.

    A wide range of isopropyl alcohol applications include processing solvents, intermediates, cleaning agents in major end user industries, such as chemicals, pharmaceuticals, personal care and cosmetics, among others.

    The isopropyl alcohol industry spans the world, with a total production capacity of 2.4 million tons in 2018. Isopropyl alcohol production is highly concentrated in Asia Pacific, North America and Western Europe, representing around 95% of global capacity in the year 2018.

    The global isopropyl alcohol market is expected to witness a considerable growth rate during the forecast period. The major factors driving the isopropyl alcohol market include the remarkable increase in the use of disinfectants across the world due to the COVID-19 pandemic and as the top choice among cleaning solvents due to the absence of added impurities.

    Isopropyl alcohol is the most common and widely used disinfectant in hospitals, pharmaceuticals, clean rooms, electronics manufacturing, and medical device manufacturing. Isopropyl alcohol is quickly antimicrobial against fungi, viruses and bacteria in solutions of 60% to 90% alcohol with 10 to 40% purified water.

    With the COVID-19 pandemic epidemic, the consumption of disinfectants has increased worldwide, driving the isopropyl alcohol market. IPA can be used as a compound disinfectant in place of ethanol, which has been favored by many countries. It is also easier to obtain isopropyl alcohol in many countries.

    Isopropyl alcohol is used in the production of hand sanitizers, rubbing alcohol, and alcohol wipes. There has been a big gap between the supply and demand for isopropyl alcohol in recent times. Manufacturers are using their full-time capacity to supply isopropyl alcohol, but are running out of alcohol due to ever-increasing demand and restrictions on the movement of goods.

    The Centers for Disease Control and Prevention (CDC) recommends using 70% isopropyl alcohol hand sanitizer in healthcare facilities to control the spread of COVID-19. To meet the continuing increase in demand for disinfectants, a temporary Food and Drug Administration (FDA) policy allows isopropyl alcohol to be used as an active ingredient in the manufacture of Alcohol-based Hand Rub (ABHR). ) by local entities that are not registered with the FDA to manufacture drugs.

    Companies are setting up new facilities to increase production to meet demand. For example, Exxon Mobil Corporation began producing medical grade hand sanitizer in Houston. The company will initially produce 160,000 gallons of hand sanitizer for donation to medical providers and first responders in Louisiana, New Jersey, New Mexico, New York, Pennsylvania and Texas.

    China is one of the major producers of isopropyl alcohol in the world. With the outbreak of the COVID-19 pandemic, the price of isopropyl alcohol at home and abroad has undergone a remarkable change. In February 2020, due to the poor quality of transport and the delay of downstream domestic projects in the country, isopropyl alcohol remained stable.

    For the production of disinfectants, ethanol was the preferred ingredient due to its lower cost and long long use across the country. However, with the epidemic spreading overseas and the growing demand for disinfectants, isopropyl alcohol has undergone enormous changes.

    Some of the major players in the global market are Royal Dutch Shell, ExxonMobil Corporation, Dow Chemical Company and Sasol Limited among others. Companies in the market are focusing on capacity additions due to the increasing demand for isopropyl alcohol in the disinfectant market.

    Main topics covered:

    1. Summary

    2. Scope and methodology of the research

    2.1 Aim and objective of the study

    2.2 Market definition

    2.3 Information on the study

    2.4 General hypotheses of the study

    2.5 Research phases

    3. Market analysis

    3.1 Presentation

    3.2 Market dynamics

    3.2.1 Drivers

    3.2.2 Constraints

    3.3 Market trends and developments

    3.4 Market opportunities

    3.5 Raw material analysis

    3.6 Business scenario

    3.7 Price trend analysis

    3.8 Supply scenario

    3.6 Regulatory policies

    3.10 Analysis of the impact of COVID-19

    4. Industry analysis

    4.1 Supply chain analysis

    4.2 Porter’s five forces analysis

    5. Market segmentation and forecast

    5.1 By level

    5.1.1 Industrial grade

    5.1.2 Pharmaceutical grade

    5.1.3 Cosmetic quality

    5.1.4 Electronic filing

    5.1.5 Other qualities

    5.2 End use

    5.2.1 Chemical

    5.2.2 Personal and cosmetic care

    5.2.3 Paints and coatings

    5.2.4 Food and drink

    5.2.5 Pharmaceuticals

    5.2.6 Others

    6. Regional market analysis

    6.1 North America

    6.1.1 United States

    6.1.2 Canada

    6.1.3 Mexico

    6.2 Europe

    6.2.1 United Kingdom

    6.2.2 Germany

    6.2.3 Italy

    6.2.4 France

    6.2.5 Russia

    6.2.6 Nordic countries

    6.2.7 Rest of Europe

    6.3 Asia-Pacific

    6.3.1 China

    6.3.2 India

    6.3.3 Japan

    6.3.4 South Korea

    6.3.5 ASEAN countries

    6.3.6 Rest of Asia-Pacific

    6.4 South America

    6.4.1 Brazil

    6.4.2 Argentina

    6.4.3 Rest of South America

    6.5 Middle East and Africa

    6.5.1 South Africa

    6.5.2 Saudi Arabia

    7. Key company profiles

    7.1 Dutch royal shell

    7.2 Dow Chemical Company

    7.3 Linde Plc

    7.4 Ecolab inc.

    7.5 LG Chem Ltd.

    7.6 Mitsui Chemicals, Inc.

    7.7 Exxon Mobil Company

    7.8 Deepak Fertilizers and Petrochemicals Corporation Limited

    7.9 PetroChina International Co., Ltd

    7.10 JXTG Nippon Oil & Energy Corporation

    7.11 Perrigo Company Plc

    7.12 Sasol Limited

    7.13 Inéos

    8. Competitive landscape

    8.1 List of notable players in the market

    8.2 Mergers and acquisitions, joint ventures and agreements

    8.3 Market share analysis

    8.4 Strategies of key actors

    9. Conclusions and recommendations

    For more information on this report, visit https://www.researchandmarkets.com/r/61tyoz

    Source link

    Sun Pharmaceutical Industries (NSE: SUNPHARMA) announced that it will increase its dividend to 2.00


    Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced that it will increase its dividend on September 17 to 2.00. This brings the dividend yield from 1.0% to 1.0%, which shareholders will be delighted with.

    Check out our latest review for Sun Pharmaceutical Industries

    Sun Pharmaceutical Industries’ revenues easily cover distributions

    A high dividend yield for a few years doesn’t mean much if it can’t be sustained. However, Sun Pharmaceutical Industries’ profits easily cover the dividend. As a result, much of what she earned was reinvested in the business.

    Next year, EPS is expected to increase 16.3%. If the dividend continues according to recent trends, we estimate that the payout ratio will be 31%, which is within the range that puts us at ease with the sustainability of the dividend.

    Historic NSEI dividend: SUNPHARMA August 7, 2021

    Dividend volatility

    Although the company has a long history of dividends, it has been cut at least once in the past 10 years. The dividend went from 1.75 in 2011 to the last annual payment of 7.50. This works out to a compound annual growth rate (CAGR) of around 16% per year over that time period. Sun Pharmaceutical Industries has increased its distributions at a rapid pace despite the dividend reduction at least once in the past. Companies that cut once often cut again, so we would be cautious about buying these stocks just for dividend income.

    Prospects for dividend growth are limited

    With a relatively volatile dividend, it is even more important to see if earnings per share increase. Sun Pharmaceutical Industries hasn’t seen much change in earnings per share over the past five years.

    In summary

    Overall, we still like to see the dividend increase, but we don’t think Sun Pharmaceutical Industries will be a good income security. In the past, payments have been volatile, but in the short term the dividend could be reliable as the company generates enough cash to cover it. Overall, we don’t think this company has the makings of a good income stock.

    It is important to note that companies with a consistent dividend policy will generate greater investor confidence than those with an erratic policy. However, there are other things for investors to consider when analyzing the performance of stocks. For example, we have chosen 1 warning sign for Sun Pharmaceutical Industries that investors should be aware of before committing capital to this stock. Looking for more high yield dividend ideas? Try our organized list of big dividend payers.

    If you decide to trade Sun Pharmaceutical Industries, use the cheapest platform * which is ranked # 1 overall by Barron’s, Interactive brokers. Trade stocks, options, futures, currencies, bonds and funds in 135 markets, all from one integrated account.

    This Simply Wall St article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in the mentioned stocks.
    *Interactive Brokers Ranked Least Expensive Broker By StockBrokers.com Online Annual Review 2020

    Do you have any feedback on this item? Are you worried about the content? Enter into a contract with us directly. You can also send an email to the editorial team (at) simplywallst.com.

    Source link

    Do Vitamin D Supplements Offer Kidney-Related Benefits for People at High Risk for Diabetes? Trial shows no significant effect on kidney outcomes – sciencedaily


    A recent clinical trial described in CJASN examined the potential of vitamin D supplementation to protect kidney health in people with prediabetes.

    In the general population, low blood levels of vitamin D have been associated with higher risks of various diseases, including type 2 diabetes and kidney disease. Sun H. Kim, MD, MS (Stanford University School of Medicine) and colleagues conducted a secondary review of the Vitamin D and Type 2 Diabetes (D2d) study to assess the effects of vitamin D supplementation on kidney health in people with pre-diabetes, a disease that increases the risk of type 2 diabetes, which in turn is the leading cause of kidney disease.

    The study randomized 2,423 overweight / obese adults with prediabetes to vitamin D3 4000 IU per day or placebo, for a median treatment duration of 2.9 years. “The D2d study is unique because we recruited people with high-risk prediabetes, with abnormal 2 of 3 glucose values, and we recruited over 2000 participants, which is the largest prevention trial of diabetes with vitamin D to date, ”said Dr. Kim.

    During the trial, there were 28 cases of worsening kidney function in the vitamin D group and 30 in the placebo group, and the mean change in kidney function during follow-up was similar in the two groups. . “Our results did not show any benefit from vitamin D supplements on kidney function. However, about 43% of the study population took vitamin D outside of the study, up to 1,000. IU per day, at the start of the study. Among those who were not taking any vitamin D alone, it was suggested that vitamin D reduced the amount of urine protein over time, which means it could have a beneficial effect on kidney health. Further studies are needed to investigate this further. “

    Dr Kim added that vitamin D supplementation is popular and that it is difficult for clinical trials of vitamin D supplementation to show a benefit if the study population is not deficient in vitamin D. “The majority of study population had sufficient vitamin D blood levels and normal kidney function, ”she said. “The benefits of vitamin D may be greatest in people with low levels of vitamin D in the blood and / or reduced kidney function.”

    Study co-authors include Irwin G. Brodsky, MD, Ranee Chatterjee, MD, MPH, Sangeeta R. Kashyap, MD, William C. Knowler, MD, DrPH, Emilia Liao, MD, Jason Nelson, MPH, Richard Pratley, MD, Neda Rasouli, MD, Ellen M. Vickery, MS, Mark Sarnak, MD, MS, and Anastassios G. Pittas, MD, MS.

    Disclosures: The authors have not reported any relevant financial disclosures associated with this publication.

    Source of the story:

    Material provided by American Society of Nephrology. Note: Content can be changed for style and length.

    Source link